Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis
- Autores
- De Paula Silva, Marina; Barrios, Bibiana Elisabet; Maccio Maretto, Lisa; Sena, Angela; Poliselli Farsky, Sandra Helena; Correa, Silvia Graciela; Oliani, Sonia María
- Año de publicación
- 2016
- Idioma
- inglés
- Tipo de recurso
- artículo
- Estado
- versión publicada
- Descripción
- TNF-α is involved in the mechanisms that initiate inflammatory bowel diseases (IBDs). Anti-TNF-α drugs, such as infliximab (IFX), cause non-responsiveness and side effects, indicating the need to investigate alternative therapies for these diseases. The anti-inflammatory protein, annexin A1 (AnxA1), has been associated with the protection of the gastrointestinal mucosa. To further address the role of endogenous AnxA1 on the TNF-α blockade efficacy in a murine model, we assessed colitis induced by Dextran Sulfate Sodium (DSS) in wild-type (WT) and AnxA1−/− Balb/c mice treated with IFX. We consistently observed endogenous AnxA1 prevented clinical and physiological manifestations of experimental colitis treated with IFX, additionally the manifestation of the disease was observed earlier in AnxA1−/− mice. Rectal bleeding, diarrhea, histological score, epithelial damages and collagen degradation caused by DSS were prevented following IFX treatment only in WT mice. IL-6 increased during colitis in WT and AnxA1−/− mice, decreasing under IFX treatment in WT. The influx of neutrophils and TNF-α secretion were largely elevated in AnxA1−/− mice when compared to WT mice. In the group WT/DSS + IFX, phagocytes were more susceptible to apoptosis following treatment with IFX. Endogenous expression of AnxA1 increased after DSS and decreased with IFX treatment, demonstrating an attenuated inflammatory response. The data indicate that AnxA1 contributes to the establishment of intestinal homeostasis after blocking of TNF-α was used as a treatment of IBD, constituting a key molecule in the mechanism of action and a potential biomarker of therapeutic efficacy.
Fil: De Paula Silva, Marina. Universidade de Sao Paulo; Brasil
Fil: Barrios, Bibiana Elisabet. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina
Fil: Maccio Maretto, Lisa. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina
Fil: Sena, Angela. Universidade de Sao Paulo; Brasil
Fil: Poliselli Farsky, Sandra Helena. Universidade de Sao Paulo; Brasil
Fil: Correa, Silvia Graciela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina
Fil: Oliani, Sonia María. Universidade de Sao Paulo; Brasil - Materia
-
ANNEXIN A1
TNF-a
COLITIS
INFLIXIMAB
THERAPY
BIOMARKER - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/46648
Ver los metadatos del registro completo
id |
CONICETDig_3105111b11654f3cf4cb4f36cafc8d5d |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/46648 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitisDe Paula Silva, MarinaBarrios, Bibiana ElisabetMaccio Maretto, LisaSena, AngelaPoliselli Farsky, Sandra HelenaCorrea, Silvia GracielaOliani, Sonia MaríaANNEXIN A1TNF-aCOLITISINFLIXIMABTHERAPYBIOMARKERhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3TNF-α is involved in the mechanisms that initiate inflammatory bowel diseases (IBDs). Anti-TNF-α drugs, such as infliximab (IFX), cause non-responsiveness and side effects, indicating the need to investigate alternative therapies for these diseases. The anti-inflammatory protein, annexin A1 (AnxA1), has been associated with the protection of the gastrointestinal mucosa. To further address the role of endogenous AnxA1 on the TNF-α blockade efficacy in a murine model, we assessed colitis induced by Dextran Sulfate Sodium (DSS) in wild-type (WT) and AnxA1−/− Balb/c mice treated with IFX. We consistently observed endogenous AnxA1 prevented clinical and physiological manifestations of experimental colitis treated with IFX, additionally the manifestation of the disease was observed earlier in AnxA1−/− mice. Rectal bleeding, diarrhea, histological score, epithelial damages and collagen degradation caused by DSS were prevented following IFX treatment only in WT mice. IL-6 increased during colitis in WT and AnxA1−/− mice, decreasing under IFX treatment in WT. The influx of neutrophils and TNF-α secretion were largely elevated in AnxA1−/− mice when compared to WT mice. In the group WT/DSS + IFX, phagocytes were more susceptible to apoptosis following treatment with IFX. Endogenous expression of AnxA1 increased after DSS and decreased with IFX treatment, demonstrating an attenuated inflammatory response. The data indicate that AnxA1 contributes to the establishment of intestinal homeostasis after blocking of TNF-α was used as a treatment of IBD, constituting a key molecule in the mechanism of action and a potential biomarker of therapeutic efficacy.Fil: De Paula Silva, Marina. Universidade de Sao Paulo; BrasilFil: Barrios, Bibiana Elisabet. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; ArgentinaFil: Maccio Maretto, Lisa. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; ArgentinaFil: Sena, Angela. Universidade de Sao Paulo; BrasilFil: Poliselli Farsky, Sandra Helena. Universidade de Sao Paulo; BrasilFil: Correa, Silvia Graciela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; ArgentinaFil: Oliani, Sonia María. Universidade de Sao Paulo; BrasilPergamon-Elsevier Science Ltd2016-09info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/46648De Paula Silva, Marina; Barrios, Bibiana Elisabet; Maccio Maretto, Lisa; Sena, Angela; Poliselli Farsky, Sandra Helena; et al.; Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis; Pergamon-Elsevier Science Ltd; Biochemical Pharmacology; 115; 9-2016; 104-1130006-2952CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/doi/10.1016/j.bcp.2016.06.012info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0006295216301381info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-29T10:20:18Zoai:ri.conicet.gov.ar:11336/46648instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-29 10:20:18.825CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis |
title |
Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis |
spellingShingle |
Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis De Paula Silva, Marina ANNEXIN A1 TNF-a COLITIS INFLIXIMAB THERAPY BIOMARKER |
title_short |
Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis |
title_full |
Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis |
title_fullStr |
Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis |
title_full_unstemmed |
Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis |
title_sort |
Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis |
dc.creator.none.fl_str_mv |
De Paula Silva, Marina Barrios, Bibiana Elisabet Maccio Maretto, Lisa Sena, Angela Poliselli Farsky, Sandra Helena Correa, Silvia Graciela Oliani, Sonia María |
author |
De Paula Silva, Marina |
author_facet |
De Paula Silva, Marina Barrios, Bibiana Elisabet Maccio Maretto, Lisa Sena, Angela Poliselli Farsky, Sandra Helena Correa, Silvia Graciela Oliani, Sonia María |
author_role |
author |
author2 |
Barrios, Bibiana Elisabet Maccio Maretto, Lisa Sena, Angela Poliselli Farsky, Sandra Helena Correa, Silvia Graciela Oliani, Sonia María |
author2_role |
author author author author author author |
dc.subject.none.fl_str_mv |
ANNEXIN A1 TNF-a COLITIS INFLIXIMAB THERAPY BIOMARKER |
topic |
ANNEXIN A1 TNF-a COLITIS INFLIXIMAB THERAPY BIOMARKER |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
TNF-α is involved in the mechanisms that initiate inflammatory bowel diseases (IBDs). Anti-TNF-α drugs, such as infliximab (IFX), cause non-responsiveness and side effects, indicating the need to investigate alternative therapies for these diseases. The anti-inflammatory protein, annexin A1 (AnxA1), has been associated with the protection of the gastrointestinal mucosa. To further address the role of endogenous AnxA1 on the TNF-α blockade efficacy in a murine model, we assessed colitis induced by Dextran Sulfate Sodium (DSS) in wild-type (WT) and AnxA1−/− Balb/c mice treated with IFX. We consistently observed endogenous AnxA1 prevented clinical and physiological manifestations of experimental colitis treated with IFX, additionally the manifestation of the disease was observed earlier in AnxA1−/− mice. Rectal bleeding, diarrhea, histological score, epithelial damages and collagen degradation caused by DSS were prevented following IFX treatment only in WT mice. IL-6 increased during colitis in WT and AnxA1−/− mice, decreasing under IFX treatment in WT. The influx of neutrophils and TNF-α secretion were largely elevated in AnxA1−/− mice when compared to WT mice. In the group WT/DSS + IFX, phagocytes were more susceptible to apoptosis following treatment with IFX. Endogenous expression of AnxA1 increased after DSS and decreased with IFX treatment, demonstrating an attenuated inflammatory response. The data indicate that AnxA1 contributes to the establishment of intestinal homeostasis after blocking of TNF-α was used as a treatment of IBD, constituting a key molecule in the mechanism of action and a potential biomarker of therapeutic efficacy. Fil: De Paula Silva, Marina. Universidade de Sao Paulo; Brasil Fil: Barrios, Bibiana Elisabet. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina Fil: Maccio Maretto, Lisa. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina Fil: Sena, Angela. Universidade de Sao Paulo; Brasil Fil: Poliselli Farsky, Sandra Helena. Universidade de Sao Paulo; Brasil Fil: Correa, Silvia Graciela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Córdoba. Centro de Investigaciones en Bioquímica Clínica e Inmunología; Argentina Fil: Oliani, Sonia María. Universidade de Sao Paulo; Brasil |
description |
TNF-α is involved in the mechanisms that initiate inflammatory bowel diseases (IBDs). Anti-TNF-α drugs, such as infliximab (IFX), cause non-responsiveness and side effects, indicating the need to investigate alternative therapies for these diseases. The anti-inflammatory protein, annexin A1 (AnxA1), has been associated with the protection of the gastrointestinal mucosa. To further address the role of endogenous AnxA1 on the TNF-α blockade efficacy in a murine model, we assessed colitis induced by Dextran Sulfate Sodium (DSS) in wild-type (WT) and AnxA1−/− Balb/c mice treated with IFX. We consistently observed endogenous AnxA1 prevented clinical and physiological manifestations of experimental colitis treated with IFX, additionally the manifestation of the disease was observed earlier in AnxA1−/− mice. Rectal bleeding, diarrhea, histological score, epithelial damages and collagen degradation caused by DSS were prevented following IFX treatment only in WT mice. IL-6 increased during colitis in WT and AnxA1−/− mice, decreasing under IFX treatment in WT. The influx of neutrophils and TNF-α secretion were largely elevated in AnxA1−/− mice when compared to WT mice. In the group WT/DSS + IFX, phagocytes were more susceptible to apoptosis following treatment with IFX. Endogenous expression of AnxA1 increased after DSS and decreased with IFX treatment, demonstrating an attenuated inflammatory response. The data indicate that AnxA1 contributes to the establishment of intestinal homeostasis after blocking of TNF-α was used as a treatment of IBD, constituting a key molecule in the mechanism of action and a potential biomarker of therapeutic efficacy. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016-09 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://purl.org/coar/resource_type/c_6501 info:ar-repo/semantics/articulo |
format |
article |
status_str |
publishedVersion |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/46648 De Paula Silva, Marina; Barrios, Bibiana Elisabet; Maccio Maretto, Lisa; Sena, Angela; Poliselli Farsky, Sandra Helena; et al.; Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis; Pergamon-Elsevier Science Ltd; Biochemical Pharmacology; 115; 9-2016; 104-113 0006-2952 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/46648 |
identifier_str_mv |
De Paula Silva, Marina; Barrios, Bibiana Elisabet; Maccio Maretto, Lisa; Sena, Angela; Poliselli Farsky, Sandra Helena; et al.; Role of the protein annexin A1 on the efficacy of anti-TNF treatment in a murine model of acute colitis; Pergamon-Elsevier Science Ltd; Biochemical Pharmacology; 115; 9-2016; 104-113 0006-2952 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.bcp.2016.06.012 info:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0006295216301381 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf |
dc.publisher.none.fl_str_mv |
Pergamon-Elsevier Science Ltd |
publisher.none.fl_str_mv |
Pergamon-Elsevier Science Ltd |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1844614182704513024 |
score |
13.070432 |